NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata’s Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata’s Co-Chief Executive Officer and G ...

Core Insights - Strata Critical Medical, Inc. has entered into a credit agreement with JPMorgan Chase Bank for secured, asset-based revolving credit loans totaling up to $30 million, with the potential to increase to $50 million under certain conditions [1][4] Group 1: Financial Strategy - The new credit facility is expected to enhance Strata's capital efficiency, allowing the company to allocate more cash towards attractive acquisition opportunities [2] - The facility will remain undrawn at the close, providing flexibility for future financing [4] Group 2: Business Operations - Strata operates one of the largest air transport and surgical services networks in the U.S. for transplant hospitals and organ procurement organizations, offering a comprehensive "one call" solution for donor organ recovery [3] - Core services include air and ground logistics, surgical organ recovery, organ placement, and normothermic regional perfusion, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers [4]

Core Insights - Strata Critical Medical, Inc. reported a revenue increase of 36.7% year-over-year to $49.3 million for Q3 2025, with organic growth of 29.0% excluding the Keystone acquisition [4][6] - The company experienced a net loss from continuing operations of $(9.7) million, an increase from $(5.6) million in the prior year [4][6] - Adjusted EBITDA for the Medical Segment rose by 93.5% to $7.6 million, reflecting strong operational performance [4][6] Financial Results - Total revenue for Q3 2025 was $49,298 thousand, compared to $36,062 thousand in Q3 2024, marking a 36.7% increase [2] - Cost of revenue increased by 32.0% to $37,684 thousand in Q3 2025 from $28,554 thousand in Q3 2024 [2] - Gross profit for Q3 2025 was $9,545 thousand, up from $5,427 thousand in the prior year, resulting in a gross margin of 19.4% [2][6] Operating Expenses - Total operating expenses increased by 27.3% to $54,920 thousand in Q3 2025 from $43,154 thousand in Q3 2024 [2] - General and administrative expenses rose by 17.5% to $16,301 thousand in Q3 2025 [2] - Selling and marketing expenses increased significantly by 53.5% to $482 thousand [2] Adjusted Metrics - Adjusted EBITDA for Q3 2025 was $4,214 thousand, a substantial increase from $67 thousand in Q3 2024 [3][4] - Medical Segment Adjusted EBITDA margin improved to 15.3% in Q3 2025 from 10.8% in Q3 2024 [5][6] - Flight Profit increased by 54.7% to $11,614 thousand, with a Flight Margin of 23.6% [3][6] Business Developments - The company raised its 2025 revenue guidance to $185-195 million, up from the previous range of $180-190 million [4][14] - Strata completed the divestiture of its Passenger business and the acquisition of Keystone Perfusion, positioning itself for long-term growth [4][14] - The integration of Keystone is reported to be progressing well, with a focus on operational efficiencies [4][6] Cash Flow and Capital Expenditures - Operating cash flow was $(37.3) million in Q3 2025, influenced by acquisition-related payments [6] - Capital expenditures for the quarter were $3.2 million, primarily for aircraft maintenance [6][13] - The company ended Q3 2025 with $75.9 million in cash and short-term investments [13]